Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/14/2008

is characterized by the rapid proliferation (growth) of abnormal white blood cells. These cells are unable to perform their regular functions and eventually crowd out healthy red and white blood cells. Leukemia cells can also spread to other parts of the body. People afflicted with AML are susceptible to increased risk of infections, anemia and bleeding.

AML is the one of the most common forms of leukemia and occurs most often in older adults -- the average age being 65. The American Cancer Society estimates that 13,410 new cases and 8,990 deaths occurred in the United States in 2007.

Although several risk factors for AML have been identified, the specific cause of AML remains unclear. AML is a potentially curable disease; but only a minority of patients are cured with current therapies. Current treatments for AML include chemotherapy, blood transfusions and stem cell transplants.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I and Phase II combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting t
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
8. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
9. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
10. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
11. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Two ... increasing in applications as their effectiveness is ... Kalorama Information.  Kalorama Information says that while ... the most powerful tool in proteomic biomarker ... MS) through its traditional techniques has struggled ...
(Date:2/26/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® and t:flex™ Insulin Pumps, today announced the ... of its common stock at a price to the ... Tandem from this offering are expected to be $56.3 ... estimated offering expenses payable by Tandem. All of the ...
(Date:2/26/2015)...  IRIDEX Corporation (NASDAQ: IRIX ) today announced ... 2014 financial results after the market closes on Thursday, ... Company will host a conference call with the investment community ... March 5, 2015 to discuss the results of the ... access the live conference call via telephone by dialing (877) ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... NEW YORK, Feb. 23, 2011 Reportlinker.com announces that ... catalogue: Global Genetic Testing Industry ... This report analyzes the worldwide markets for Genetic Testing ... by the following segments: Prenatal and Newborn Genetic Testing, ...
... YORK, Feb. 23, 2011 Reportlinker.com announces that ... its catalogue: Global Medical ... http://www.reportlinker.com/p098273/Global-Medical-Imaging-Equipment-Services-Industry.html This report analyzes ... in US$ Million by the following Product segments: ...
Cached Medicine Technology:Reportlinker Adds Global Genetic Testing Industry 2Reportlinker Adds Global Medical Imaging Equipment Services Industry 2
(Date:2/28/2015)... The Classic Denture Center , ... special. Throughout all of March patients can receive ... service can help overall mouth health and ... may notice certain symptoms that suggest the denture teeth ... include: , 1.    Pain, clicking, and popping in the joints, ...
(Date:2/28/2015)... 28, 2015 A study out of ... gene therapy procedure for the treatment of a hereditary ... Authored by Dr. Robert MacLaren, professor of ... the Lancet Medical Journal on January 16, 2014 , ... rare genetic disorder that mostly affects men and leads ...
(Date:2/28/2015)... Beach, CA (PRWEB) February 28, 2015 ... needs of Central Coast area residents, recently announced a ... System. It’s a treatment option for new and ... kick off 2015 with a bright, white smile, Dr. ... discounted price of $299, marked down from the regular ...
(Date:2/28/2015)... New York, NY (PRWEB) February 28, 2015 ... DIY Phishing Kits Make It Easy For Scammers To Steal ... about anyone can get their hands on a DIY phishing ... But it also touched on another important point about ... ways these kits are often implemented, “like compromising legitimate content ...
(Date:2/28/2015)... 28, 2015 “ Powermod ” was featured ... takes a look at the latest and coolest technology products ... for NewsWatch and a technology expert, conducted the review and ... charging solutions. , Getting stuck with a low battery and ... problem that people face on a daily basis. Even when ...
Breaking Medicine News(10 mins):Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2
... million people around the world every year, and chlororquine, ... becoming ineffective, reports NDTV., ,A national survey indicates ... of plasmodium falsiparum, which causes a severe form of ... ,Thus, the government has decided to replace the ...
... Superior Court jury in Seattle, Dr. Charles Momah, an obstetrician ... of rape and two counts of indecent liberties against four ... could face 16 years in prison if convicted on all ... not guilty last year to two counts of rape and ...
... considered as an important breakthrough in our still limited ... new gene linked to major mental illness // ... to increase the risk of schizophrenia and depression. ... together with scientists from the pharmaceutical company Merck, Sharp ...
... a golden statement that has withstood the test of time. ... survey revealing that nearly one-third of all cancers // can ... of. The study was part of an overall Initiative for ... the march, accounting for nearly 21 % of all cancers. ...
... conducted by the scientists at the University of Wisconsin ... // into mapping software and reached their conclusions. The ... the climate change are the poor countries, who are ... study's lead author, Jonathan Patz, a professor at the ...
... bird flu cases in China and Indonesia, the World Health ... been stricken with the H5N1 // avian influenza virus that ... 150 million birds. ,More than half the people ... ,WHO affirms the announcement from Beijing officials November 16 that ...
Cached Medicine News:Health News:A Step Towards Unraveling The Schizophrenia And Depression Mystery 2Health News:One Third Of All Cancers Preventable! 2
... dual lumen M.R.I. model is ... mm inner diameter catheters (each ... offer larger lumen equivalency while ... lumen offset-tip catheters are available ...
The standard-sized titanium port may be ordered with a silicone or polyurethane catheter. The silicone catheter is available with inner diameter sizes of 0.9, 1.0, 1.4, 1.6 mm. The polyurethane cathe...
... catheters connect to the CoolGard 3000 Thermal ... target temperature input by the user. It ... and automatically adjusts the temperature of the ... consistent maintenance of temperature. The CoolGard 3000 ...
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: